Sugi Predict

Sugi Predict / Compounds / SCHEMBL998210

SCHEMBL998210

SCHEMBL998210

Nc1cccc2cncc(F)c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 3/20 0.46
▸ LMNA P02545 2/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.35
▸ HPGD P15428 3/20 0.35
▸ TSHR P16473 2/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ KEAP1 Q14145 1/20 0.35
▸ ROCK2 O75116 2/20 0.35
▸ ROCK1 Q13464 2/20 0.35
▸ PLK4 O00444 1/20 0.35
▸ NQO2 P16083 1/20 0.35
▸ MARK3 P27448 1/20 0.35
▸ MAP2K3 P46734 1/20 0.35
▸ CDK9 P50750 1/20 0.35
▸ PRKAG1 P54619 1/20 0.35
▸ PRKCD Q05655 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27191914 0.84 CYP1A2 (0.41) CYP3A4LMNACYP1A2CYP2D6CYP2C9
Hydrochloric Acid SCHEMBL30034692 0.82 CYP1A2 (0.40) CYP3A4LMNACYP1A2CYP2D6CYP2C9
SCHEMBL637008 0.81 CYP3A4 (0.50) CYP3A4LMNACYP1A2CYP2D6CYP2C9
SCHEMBL31732851 0.81 CYP3A4 (0.50) CYP3A4LMNACYP1A2CYP2D6CYP2C9
SCHEMBL17228307 0.79 CYP3A4 (0.42) CYP3A4LMNACYP1A2CYP2D6CYP2C9
SCHEMBL18495139 0.78 ACHE (0.39) CYP3A4CYP1A2ALDH1A1HPGDTSHR
SCHEMBL4078324 0.76 JAK2 (0.45) CYP3A4LMNACYP1A2CYP2D6CYP2C9
SCHEMBL30706725 0.76 JAK2 (0.45) CYP3A4LMNACYP1A2CYP2D6CYP2C9
SCHEMBL18599581 0.76 ROCK2 (0.35) ROCK2ROCK1PLK4NQO2MARK3
SCHEMBL5657552 0.76 CYP3A4 (0.46) CYP3A4LMNACYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113227054-B ROCK kinase inhibitors 切尔韦洛治疗有限责任公司 2025-04-11 — — CN disclosed
EP-3877364-B1 ROCK KINASE INHIBITORS Cervello Therapeutics LLC (US) 2024-08-21 — — EP disclosed
CN-117946002-A Synthesis method of rosuvastatin key intermediate 安徽峆一药业股份有限公司 2024-04-30 — — CN disclosed
US-11912719-B2 Substituted isoquinolines as rock kinase inhibitors CERVELLO THERAPEUTICS, LLC. (US) 2024-02-27 — — US disclosed
US-11912719-B2 Substituted isoquinolines as rock kinase inhibitors CERVELLO THERAPEUTICS, LLC. (US) 2024-02-27 — — US disclosed
US-11912719-B2 Substituted isoquinolines as rock kinase inhibitors CERVELLO THERAPEUTICS, LLC. (US) 2024-02-27 — — US disclosed
US-20220119406-A1 SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS Cervello Therapeutics LLC (US) 2022-04-21 — — US disclosed
US-20220119406-A1 SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS Cervello Therapeutics LLC (US) 2022-04-21 — — US disclosed
US-11248004-B2 Substituted isoquinolines as rock kinase inhibitors CERVELLO THERAPEUTICS, LLC. (US) 2022-02-15 — — US disclosed
US-11248004-B2 Substituted isoquinolines as rock kinase inhibitors CERVELLO THERAPEUTICS, LLC. (US) 2022-02-15 — — US disclosed
EP-2130828-A1 SULFONAMIDE DERIVATIVE Asahi Kasei Pharma Corporation (JP) 2009-12-09 — — EP disclosed
US-7618984-B2 Sulfonamide compound ASAHI KASEI PHARMA CORPORATION (JP) 2009-11-17 — — US disclosed
US-20090209765-A1 PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF KOWA CO., LTD. (JP) 2009-08-20 — — US disclosed
US-20090209765-A1 PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF KOWA CO., LTD. (JP) 2009-08-20 — — US disclosed
US-20090209765-A1 PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF KOWA CO., LTD. (JP) 2009-08-20 — — US disclosed
US-20090048223-A1 Sulfonamide compound ASAHI KASEI PHARMA CORPORATION (JP) 2009-02-19 — — US disclosed
EP-1932841-A1 SULFONAMIDE COMPOUND Asahi Kasei Pharma Corporation (JP) 2008-06-18 — — EP disclosed
EP-1852421-A1 PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF Kowa Company, Ltd. (JP) 2007-11-07 — — EP disclosed
EP-1852421-A1 PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF Kowa Company, Ltd. (JP) 2007-11-07 — — EP disclosed
US-20070179127-A1 Sulfonamide compound ASAHI KASEI PHARMA CORPORATION (JP) 2007-08-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11248004-B2 Substituted isoquinolines as rock kinase inhibitors ROCK1, ROCK2, CIT CYP3A4 3330/4885LMNA 1820/4885CYP1A2 1966/4885
US-20070179127-A1 Sulfonamide compound MYLK, MYLK2, MYLK3 CYP3A4 2078/4885LMNA 1303/4885CYP1A2 1727/4885
US-11912719-B2 Substituted isoquinolines as rock kinase inhibitors ROCK1, ROCK2, CIT CYP3A4 3330/4885LMNA 1820/4885CYP1A2 1966/4885
US-20090048223-A1 Sulfonamide compound ALK, AKT1, ARAF CYP3A4 2359/4885LMNA 2215/4885CYP1A2 1718/4885
US-20090209765-A1 PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF SALL4, STS, SFPQ CYP3A4 104/4885LMNA 4087/4885CYP1A2 968/4885
US-20220119406-A1 SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS ROCK1, ROCK2, CIT CYP3A4 3330/4885LMNA 1820/4885CYP1A2 1966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.